Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 12:57 PM
Ignite Modification Date:
2025-12-24 @ 12:57 PM
NCT ID:
NCT02468661
Eligibility Criteria:
Inclusion Criteria:
* Locally advanced or metastatic NSCLC
* EGFR mutation (L858R and /or ex19del)
* cMET amplification by FISH (GCN ≥ 6),
* Acquired resistance to EGFR TKI (1st or 2nd generation)
* ECOG performance status (PS) ≤ 1.
Exclusion Criteria:
* Prior treatment with 3rd generation TKI
* PhaseII : Prior treatment with any of the following agents:
* Crizotinib, or any other cMET inhibitor or HGF-targeting inhibitor.
* Concomitant EGFR TKI and platinum based chemotherapy as first line regimen.
* Platinum-based chemotherapy as first line treatment
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02468661
Study Brief:
Protocol Section:
NCT02468661